0 651

Cited 6 times in

Cited 0 times in

Vaginal compared with intramuscular progestogen for preventing preterm birth in high-risk pregnant women (VICTORIA study): a multicentre, open-label randomised trial and meta-analysis

Authors
 Choi, S-J  ;  Kwak, D. W.  ;  Kil, K.  ;  Kim, S-C  ;  Kwon, Ja Young  ;  Kim, Y. H.  ;  Na, S.  ;  Bae, J-G  ;  Cha, H-H  ;  Shim, J-Y  ;  Oh, K. Y.  ;  Lee, K. A.  ;  Kim, S. M.  ;  Cho, I. A.  ;  Lee, S. M.  ;  Cho, G. J.  ;  Jo, Y. S.  ;  Choi, G. Y.  ;  Choi, S. K.  ;  Hur, S. E.  ;  Hwang, H. S.  ;  Kim, Y. J. 
Citation
 BJOG: An International Journal of Obstetrics and Gynaecology, Vol.127(13) : 1646-1654, 2020-12 
Journal Title
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
ISSN
 1470-0328 
Issue Date
2020-12
Keywords
Preterm birth ; prevention ; progestogen ; short cervical length
Abstract
Objective To compare the efficacy of two types of progestogen therapy for preventing preterm birth (PTB) and to review the relevant literature. Design A multicentre, randomised, open-label, equivalence trial and a meta-analysis. Setting Tertiary referral hospitals in South Korea. Population Pregnant women with a history of spontaneous PTB or short cervical length (<25 mm). Methods Eligible women were screened and randomised at 16-22 weeks of gestation to receive either 200 mg of vaginal micronised progesterone daily (vaginal group) or an intramuscular injection of 250 mg 17 alpha-hydroxyprogesterone caproate weekly (IM group). Stratified randomisation was carried out according to participating centres and indications for progestogen therapy. This trial was registered at (NCT02304237). Main outcome measure Preterm birth (PTB) before 37 weeks of gestation. Results A total of 266 women were randomly assigned and a total of 247 women (119 and 128 women in the vaginal and IM groups, respectively) were available for the intention-to-treat analysis. Risks of PTB before 37 weeks of gestation did not significantly differ between the two groups (22.7 versus 25.8%,P = 0.571). The difference in PTB risk between the two groups was 3.1% (95% CI -7.6 to 13.8%), which was within the equivalence margin of 15%. The meta-analysis results showed no significant differences in the risk of PTB between the vaginal and IM progestogen treatments. Conclusion Compared with vaginal progesterone, treatment with intramuscular progestin might increase the risk of PTB before 37 weeks of gestation by as much as 13.8%, or reduce the risk by as much as 7.6%, in women with a history of spontaneous PTB or with short cervical length. Tweetable abstract Vaginal and intramuscular progestogen showed equivalent efficacy for preventing preterm birth before 37 weeks of gestation.
DOI
10.1111/1471-0528.16365
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers
Yonsei Authors
Kwon, Ja Young(권자영) ORCID logo https://orcid.org/0000-0003-3009-6325
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/182641
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links